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Objectives: To evaluate dolutegravir and elvitegravir/cobicistat pharmacokinetics in HIV-negative volunteers up
to 10 days after drug cessation.
Methods: Healthy volunteers received 50 mg of dolutegravir once-daily for 10 days, then underwent a 9 day
wash-out period, and then received elvitegravir/cobicistat as part of Stribildw (245 mg of tenofovir, 200 mg of
emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days. Serial pharmacokinetic (PK) sampling
occurred prior to the final dose of each course and at regular intervals for up to 216 h (10 days) after drug ces-
sation. Concentrations were determined by LC-MS/MS, and PK parameters were illustrated as geometric mean
and 90% CI.
Results: Seventeen volunteers completed the study. For dolutegravir, plasma terminal elimination t1/2 to the
last measurable concentration (within 216 h) was longer than its t1/2 within the dosing interval (0 –24 h):
14.3 h (12.9–15.7 h) versus 23.1 h (19.7–26.6 h); conversely, the terminal elimination t1/2 for elvitegravir was
lower than its t1/2 within the dosing interval (0 –24 h): 10.8 h (9.7 –13.0 h) versus 5.2 h (4.7 –6.1 h).
Dolutegravir concentrations were above the protein-adjusted (PA) IC90 (64 ng/mL) in 100% of subjects after
36 and 48 h and in 94% after 60 and 72 h. All subjects had detectable dolutegravir concentrations at 96 h, a
mean of 23.5% above the IC90. Elvitegravir concentrations were above the PA IC95 (45 ng/mL) in 100% of subjects
at 24 h, 65% at 36 h but 0% after 48 h.
Conclusions: Our data show marked differences in the elimination rates of dolutegravir and elvitegravir following
treatment interruption, which is likely to impact the extent to which drug doses can be delayed or missed. They
suggest that clinical differences may emerge in patients who have suboptimal adherence.
Introduction
HIV-1 integrase strand transfer inhibitors (InSTIs) are the newest
class of approved ART. As HIV-1 integrase has no equivalent in
host cells, InSTIs exhibit minimal related interference with normal
cellular processes and, as such, their safety profile differs from
that of other ART classes.1 Consequently, InSTIs are increasingly
favoured over older drug classes as they demonstrate high efficacy
and tolerability with low toxicity when prescribed in combination
with two nucleoside or nucleotide reverse transcriptase inhibitors.
Whilst raltegravir was the first licensed InSTI, elvitegravir and,
more recently, dolutegravir have now been approved for use in the
USA and Europe.2 Elvitegravir is prescribed in combination with
the cytochrome P450 3A4 (CYP3A4) inhibitor cobicistat, which
enhances elvitegravir exposure enabling once-daily dosing. Both
elvitegravir and dolutegravir are available in fixed-dose combina-
tions taken once-daily, facilitating the potential for adherence.3
Despite advances in ART facilitating better adherence, delayed
or omitted doses still occur, potentially compromising virological
control and risking the emergence of drug resistance. Therefore,
plasma pharmacokinetic (PK) data after cessation of antiretroviral
drugs are important to understand the management of late and
missed doses. Drug persistence in plasma is dependent on its t1/2
(which itself depends on CL and V).4 Antiretroviral agents with
longer t1/2 may be more forgiving and allow for forgotten doses,
especially if drug concentrations remain above sub-therapeutic
concentrations until the patient reinitiates drug intake.
In addition to information on the ‘forgiveness’ of dosing regi-
mens, PK data after cessation of drug intake may inform the
appropriateness of specific compounds for HIV pre-exposure
prophylaxis and for alternative treatment strategies tailored
to facilitate adherence, such as were seen in the FOTO study.5
That study showed that short-cycle structured treatment inter-
ruptions (dosing for 5 days consecutively followed by a 2 day
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break) with ART containing tenofovir/emtricitabine and efavirenz,
all long t1/2 agents, was non-inferior to daily therapy whilst being
preferred by patients, with no virological failures reported. More
recent data from the BREATHER study of developing and devel-
oped countries demonstrated similar efficacy in adolescents on
efavirenz.6
In vivo data for dolutegravir and elvitegravir/cobicistat concen-
tration decay after intake cessation have not been previously
described. In this study, we independently evaluated the plasma
PK parameters of once-daily dolutegravir and once-daily elvitegra-
vir/cobicistat in HIV-negative healthy volunteers up to 10 days fol-
lowing cessation of drug intake.
Materials and methods
Participants
Written informed consent was obtained from male and non-pregnant,
non-lactating female healthy volunteers aged between 18 and 65 years
and with a BMI between 18 and 35 kg/m2. Participants were excluded if
they had any significant acute or chronic medical illness; abnormal phys-
ical examination, ECG or clinical laboratory determinations; positive
screens for HIV, hepatitis B or C; current or recent (within 3 months)
gastrointestinal disease; clinically relevant alcohol or drug use that the
investigator felt would adversely affect compliance with trial procedures;
exposure to any investigational drug or placebo within 3 months of the
first dose of the study drug; use of any other drugs, including over the
counter medications and herbal preparations, within 2 weeks before the
first dose of the study drug; and previous allergy to any of the constituents
of the pharmaceuticals administered during the trial.
Study design
This was a 38 day, open-label, two-phase PK trial conducted at the
St Stephen’s Centre, Chelsea and Westminster Hospital, London, UK.
The study protocol was approved by the London Westminster Research
Ethics Committee as well as the Medicines and Healthcare Products
Regulatory Agency in the UK and was conducted according to Good
Clinical Practice and the Declaration of Helsinki (EudraCT 2014-001421-33,
NCT02219217).
At screening, participants had a clinical assessment and routine
laboratory investigations performed. The safety and tolerability of study
medications were evaluated throughout the trial using the NIAID
Division of AIDS table for grading the severity of adult and paediatric
adverse events to characterize abnormal findings (published 2004), vital
signs, physical examinations and clinical laboratory investigations.
After successful screening, participants were administered 50 mg
of dolutegravir once daily for 10 days for the first phase of the study. They
were admitted to the unit on day 10. Blood samples for dolutegravir PK
assessment were taken before the final dose in the morning of day 10 and
at 2, 4, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 and 216 h post dose.
After the wash-out period of 9 days, on day 20, all subjects were admi-
nistered Stribildw (245 mg of tenofovir disoproxil fumarate, 200 mg of
emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) once
daily for 10 days for the second phase of the trial, and blood samples
were taken at the same intervals as above, prior to and over 216 h after
the last dose.
On the PK days, the study medication was taken with a standardized
breakfast (626 kcal) and 240 mL of water and subjects were admitted
for 12 h, after which they could leave the unit and return at regular inter-
vals to complete sampling over 9 days.
Compliance with study drug administration was assessed through pill
counting by the study staff.
Analytical and PK methods
Plasma collection of dolutegravir, elvitegravir
and cobicistat
Blood samples were collected into lithium heparin-containing blood tubes
(6 mL) at each timepoint, immediately inverted several times and then
kept on ice or refrigerated until centrifugation. Within 30 min of blood col-
lection, each blood sample was centrifuged for 10 min at 1200 g at 48C.
Plasma was then aliquotted equally into three 2.0 mL tubes (Sarstedt,
Germany) and stored at 2208C. Samples were shipped on dry ice to the
Liverpool Bioanalytical Facility (Good Clinical Laboratory Practice accre-
dited) for analysis.
Quantification of plasma dolutegravir, elvitegravir,
cobicistat
Concentrations of dolutegravir, elvitegravir and cobicistat in plasma were
determined using liquid– liquid extraction (with methyl tertiary-butyl
ether) of analyte and internal standard (d5-dolutegravir, d6-elvitegravir,
or quinoxaline) using validated HPLC tandem MS and analytical conditions
substantially as previously described.7 The lower limit of quantification
(LLOQ) was 0.75 ng/mL for all components. For concentrations below
the assay LLOQ, a value of one-half of the quantification limit (0.325 ng/mL)
was used.
The assay was validated over a calibration range of either 10–4000 or
0.75–20 ng/mL (for concentrations below the LLOQ of the initial assay).
Accuracy (percentage bias) was between 98.0% and 104.6% (dolutegra-
vir), 101.8% and 106.7% (elvitegravir) and 99.8% and 106.2% (cobicistat),
and precision was between 4.6% and 6.2% (dolutegravir), 4.3% and 5.6%
(elvitegravir) and 5.0% and 6.0% (cobicistat).
Pharmacokinetic and statistical analysis
The calculated PK parameters for dolutegravir, elvitegravir and cobicistat
were the plasma concentration measured 24 h after the observed dose
(C24), the maximum observed plasma concentration (Cmax) and the area
under the plasma concentration curve from 0 to 24 h (AUC0 – 24). The t1/2
was determined from the elimination phase within the normal dosing
interval of 0–24 h and as a terminal elimination t1/2 to the last measurable
concentration within 216 h. All PK parameters were calculated using
actual blood sampling time and non-compartmental modelling techni-
ques (WinNonlin Phoenix, version 6.1; Pharsight, Mountain View, CA).
Descriptive statistics, including geometric mean (GM) and 90% CI were
calculated for dolutegravir, elvitegravir and cobicistat PK parameters. GMs
were compared with the suggested therapeutic targets that were estab-
lished in vitro and are available in the current literature for each drug.
These targets are the protein binding-adjusted (PA) IC90 for dolutegravir
(64 ng/mL) and the PA IC95 for elvitegravir (45 ng/mL).
8,9
Interindividual variability in drug PK parameters was expressed as a
percentage coefficient of variation [CV, (standard deviation/mean)×100].
Results
Study population
Seventeen participants completed all phases of the study. The
median age was 39 years (range 26–52 years), and the median
BMI was 26 kg/m2 (range 19 –34 kg/m2). Twelve participants
were female; nine described themselves as white and eight as
black. No serious breach to the protocol was recorded during
the study. The study drugs were well tolerated, and no grade 3
or 4 adverse event was reported.
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Plasma dolutegravir, elvitegravir and cobicistat
pharmacokinetics
GM plasma concentration versus time curves for dolutegravir,
elvitegravir and cobicistat are shown in Figure 1, and PK para-
meters summarized in Table 1.
Dolutegravir plasma pharmacokinetics
The GM terminal elimination t1/2 for dolutegravir was 23.1 h (90%
CI 19.7–26.6 h). This value was higher than the t1/2 measured
over the dosing interval of 24 h (GM 14.3 h; 90% CI 12.9–15.7 h).
The PA IC90 for dolutegravir is 64 ng/mL.
8 GM plasma dolute-
gravir concentrations were measured above this value at 24, 36,
and 48 h post drug intake cessation (Table 2). At 60 and 72 h post
drug intake cessation, 16 out of 17 subjects had dolutegravir
concentrations above the IC90 (Table 2). At 96 h post dose, dolute-
gravir GM concentration fell below the IC90 (52.2 ng/mL, range
6.9–153.0 ng/mL), with four subjects remaining above the IC90
(Table 2).
Elvitegravir plasma pharmacokinetics
Elvitegravir GM terminal elimination t1/2 to the last measurable
concentration was 5.2 h (90% CI 4.7–6.1 h), which was lower
than the t1/2 measured over the dosing interval of 24 h (GM
10.8 h, 90% CI 9.7–13.0 h).
The suggested PA IC95 for elvitegravir is 45 ng/mL.
9 All subjects
had elvitegravir concentrations above the IC95 at 24 h post dose.
Elvitegravir GM plasma concentration was above the IC95 36 h
post drug cessation (GM 57 ng/mL, range 11–296 ng/mL); however,
only 11/17 subjects had elvitegravir concentrations above the IC95.
The elvitegravir GM concentration fell below the IC95 at 48, 60 and
72 h post drug intake cessation, and elvitegravir concentrations
were below the LLOQ in all study participants at 96 h post the final
dose (Table 2).
Cobicistat plasma pharmacokinetics
The GM terminal elimination t1/2 to the last measurable concen-






















Figure 1. GM drug concentration-time curves of dolutegravir, elvitegravir and cobicistat. Vertical bars represent 90% CIs.
Table 1. Plasma dolutegravir and elvitegravir/cobicistat PK parameters
PK parameters
Dolutegravir Elvitegravir Cobicistat
GM (90% CI) CV% GM (90% CI) CV% GM (90% CI) CV%
Tmax (h) 3.1 (2.4–3.9) 55 4.5 (4.1–4.6) 39 3.1 (2.9–3.7) 30
Cmax (ng/mL) 3908 (3571–4245) 21 1675 (1557–1884) 24 127 (1184–1437) 24
AUC0 –24 (ng.h/mL) 55505 (51368–59642) 18 22965 (21483–25592) 22 10686 (9692–12522) 32
C24 (ng/mL) 1324 (1178–1470) 27 419 (387–501) 32 28 (24–48) 85
C48 (ng/mL) 427 (362–499) 35 8 (8–15) 78 7 (6–9) 47
t1/2 (0–24) (h) 14.3 (12.9–15.7) 23 10.8 (9.7–13.0) 31 3.54 (3.3–3.9) 20
t1/2 (last) (h) 23.1 (19.7–26.6) 16 5.2 (4.7–6.1) 18 18.2 (16.2–26.0) 57
C48, 48 h post-dose concentration.
Dolutegravir and elvitegravir pharmacokinetics
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was higher than the t1/2 measured over the dosing interval of 24 h
(GM 3.5 h, 90% CI 3.3–3.9).
Discussion
We report here the steady-state plasma pharmacokinetics of
dolutegravir at 50 mg once daily and elvitegravir at 150 mg
once daily boosted by cobicistat (150 mg) over 216 h following
drug intake cessation in 17 male and female healthy volunteers.
Our data fully characterize for the first time the PK forgiveness of
the two newest InSTIs.
Following achievement of steady-state, GM dolutegravir con-
centrations remained above the suggested plasma PA IC90 of
64 ng/mL for up to 72 h post drug intake cessation, with most
subjects (94%) showing concentrations above the PA IC90 at this
time. The GM concentration for elvitegravir was above the sug-
gested PA IC95 of 45 ng/mL at 24 and 36 h post drug cessation,
with 65% of participants above this cut-off at the latter timepoint,
but it had fallen below the PA IC95 by 48 h post dose (with no par-
ticipant above this cut-off then). It is important to note that these
agents have no established minimum effective therapeutic con-
centrations. Being above the (partially PA) in vitro PA IC95 does
not imply that the exposures are sufficient for a fully effective in
vivo drug exposure, especially when optimal drug exposures are
needed during induction of virological control.
Plasma interindividual variability (CV) in dolutegravir and elvite-
gravir C24 was 27% and 32%, respectively. These values are lower
than those measured for the third available InSTI, raltegravir
(53%–220%).10
Interestingly, whilst dolutegravir is not dependent on a booster
and concentrations are persistent in the systemic circulation for a
prolonged period, concentrations of elvitegravir were observed to
drop when the concentrations of its booster cobicistat fell below a
certain level. The terminal t1/2 (0 to 216 h) was longer than the t1/2
within the dosing interval (0–24 h) for dolutegravir, whilst the
opposite was true for elvitegravir (23.1 versus 14.3 h and 5.2 ver-
sus 10.8 h, respectively). One explanation could be that this phe-
nomenon is due to saturation of metabolic processes at higher
concentrations, meaning a change in rate of CL as cobicistat con-
centrations fall to non-saturating levels.
Of note, the single-tablet formulations of dolutegravir and elvite-
gravir contain partner NRTIs of varying t1/2 values. We have previously
shown the plasma t1/2 of abacavir and lamivudine to be 3–4 h and
5.7 h, respectively, with intracellular half-lives of the active tripho-
sphorylated metabolite of abacavir (carbovir) and the active tripho-
sphorylated metabolite of lamivudine to be 14.1 h and 19 h,
respectively.11 Exposures differ between male and female subjects.
The longer t1/2 of tenofovir and emtricitabine, both in plasma
and PBMC (31 h and 37 h and 164 h and 39 h, respectively),2 – 5
may also be important to the clinical forgiveness of these regi-
mens and the specific resistance mutations that are observed at
failure. Dolutegravir is currently available in co-formulation with
abacavir and lamivudine; it is interesting to note that the t1/2 of
carbovir and the active triphosphorylated metabolite of lamivu-
dine match dolutegravir’s t1/2 both within the dosing interval
(14 h) and to the last measurable concentration (23 h).
In patients with chronic diseases, poor adherence to medications
has been shown to be common,12 and in the context of HIV infection,
the potential repercussions can be serious since if drug concentrations
drop to sub-therapeutic levels after missed doses, there is a risk of
emergence of drug-resistant HIV strains, which limit future thera-
peutic options. Great efforts are made to support and encourage
patients with respect to the importance of adherence, but it is often
unclear how delayed a dose was or how many doses can be omitted
before efficacy is lost. Therefore, identifying persistence of therapeutic
concentrations is essential for robust patient care. Additionally,
understanding the PK attributes of a drug and, more specifically, PK
forgiveness can also allow identification of potential candidates for
pre-exposure prophylaxis and alternative treatment strategies
where optimal dosing frequency needs to be characterized.
Table 2. Summary of dolutegravir and elvitegravir concentrations (expressed as GM) and detectability at significant timepoints
Time after last dose (h) Variable Dolutegravir (IC90 64 ng/mL) Elvitegravir (IC95 45 ng/mL)
24 GM concentration (ng/mL) 1324 419
Proportion detectable in plasma 100% (17/17) 100% (17/17)
Proportion above IC90 or IC95 100% (17/17) 100% (17/17)
36 GM concentration (ng/mL) 711 57
Proportion detectable in plasma 100% (17/17) 100% (17/17)
Proportion above IC90 or IC95 100% (17/17) 65% (11/17)
48 GM concentration (ng/mL) 427 8.3
Proportion detectable in plasma 100% (17/17) 94% (16/17)
Proportion above IC90 or IC95 100% (17/17) 0%
60 GM concentration (ng/mL) 240 2.5
Proportion detectable in plasma 100% (17/17) 76% (13/17)
Proportion above IC90 or IC95 94% (16/17) 0%
72 GM concentration (ng/mL) 131 1.7
Proportion detectable in plasma 100% (17/17) 53% (9/17)
Proportion above IC90 or IC95 94% (16/17) 0%
96 GM concentration (ng/mL) 52.2 —
Proportion detectable in plasma 100% (17/17) 0%
Proportion above IC90 or IC95 23.5% (4/17) —
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Nevertheless, one of the limitations of this study is that it was
carried out in healthy volunteers to avoid dose delays in patients
infected with HIV. As such, PK/pharmacodynamic conclusions or
speculation on what in vivo concentrations are needed to main-
tain efficacy cannot be robustly drawn. Ideally, pharmacody-
namic data are required to draw definite conclusions on how
late a drug dose can be or on whether drug doses can be missed
without the risk of failure.
Indeed, discrepancies in antiretroviral drug pharmacokinetics
between healthy volunteers and people living with HIV have been
previously described, particularly for the PIs.13 Such differences are
thought to be related to physiological variability in several para-
meters between the two populations, including CYP450 activity
and a-1-acid glycoprotein expression.13 Since dolutegravir and elvi-
tegravir are new drugs, data on differences in concentrations
between healthy volunteers and HIV-infected subjects have not
been presented to date. However, today there are no data indicat-
ing any significant difference in pharmacokinetics of dolutegravir or
elvitegravir between healthy and HIV-infected subjects.
A further limitation of the study is the use of cut-off values cal-
culated from in vitro data to define therapeutic concentrations in
vivo. However, minimum effective concentrations of dolutegravir
and elvitegravir have not been established, and the PA IC90 and PA
IC95 are currently the only surrogates available to define efficacy
in the context of drug exposure.
Additionally, the same in vitro threshold is not available for
both drugs, the PA IC90 and PA IC95, for dolutegravir and elvitegra-
vir respectively, are today the only reference values available to
define drug efficacy in the context of drug exposure.
Finally, dolutegravir was administered alone in this study,
whilst elvitegravir/cobicistat were co-administered as part of a
single tablet combination therapy with tenofovir/emtricitabine.
Dolutegravir administered within an abacavir/lamivudine fixed
combination was considered not justified, based on the risk of
abacavir hypersensitivity in HIV-negative subjects14 and the
known lack of effect of backbone NRTIs on the pharmacokinetics
of either elvitegravir or dolutegravir.
Of note, it is not impossible that a minority of patients had
residual exposure to low-dose dolutegravir at the start of the elvi-
tegravir phase of our study, but this exposure is likely to be min-
imal, as PK sampling for elvitegravir was carried out 19 days after
the last dose of dolutegravir and, importantly, dolutegravir has no
known impact on elvitegravir/cobicistat metabolic pathways.
In conclusion, our data show that there are marked differences
in the elimination rates of dolutegravir and elvitegravir following
treatment interruption. These differences are likely to affect the
extent to which drug doses can be delayed or missed, and they
suggest that clinical differences may emerge in patients who
have suboptimal adherence. However, the net risk or benefit of
these elimination characteristics depends very much upon all
the components of the regimen.
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